“It is a great honor to be named one of the Best Places to Work in Pennsylvania, and I’m pleased to share this award with all of my colleagues who help make Aclaris an exceptional company,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. “We have built an extraordinary team of people who are committed to developing and commercializing new medical and aesthetic dermatology treatment options for patients with visible skin and hair conditions.”
This survey and awards program was designed to identify, recognize and honor the best places of employment in
To be considered for participation, companies had to fulfill the following eligibility requirements:
- Be a for-profit or not-for-profit business
- Be a publicly or privately held business
- Have a facility in
- Have at least 15 employees working in
- Be in business a minimum of one year
Companies from across the state entered the two-part process to determine the 100 Best Places to Work in PA. The first part of this process was evaluating each nominated company's workplace policies, practices, philosophies, systems and demographics. This part of the process was worth approximately 25% of the total evaluation. The second part consisted of an employee survey to measure the employee experience. This part of the process was worth approximately 75% of the total evaluation. The combined scores determined the top companies and the final ranking.
Aclaris will be recognized at the Best Places to Work in PA awards banquet on
In addition to the public/private partnership, the program is supported by the following organizations: Lead Sponsor—Team Pennsylvania Foundation; Major Sponsor—Saul Ewing Arnstein & Lehr; Founding Partners—Team Pennsylvania Foundation, the
For more information on the Best Places to Work in PA, visit www.bestplacestoworkinpa.com or contact
About Aclaris Therapeutics, Inc.
Contact:
Aclaris Contact
Vice President / Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
TogoRun
917-242-1087
M.Caprino@togorun.com
Source: Aclaris Therapeutics, Inc.